

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): August 9, 2016**

---

**SEMLER SCIENTIFIC, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**001-36305**  
(Commission File Number)

**26-1367393**  
(IRS Employer Identification No.)

**2330 NW Everett St.**  
**Portland, Oregon**  
(Address of principal executive offices)

**97210**  
(Zip Code)

Registrant's telephone number, including area code: **(877) 774-4211**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

### Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, Semler Scientific, Inc. (the “Company”) received a deficiency notice (the “Notice”), dated August 11, 2015, from the Nasdaq Stock Market (“NASDAQ”) notifying it that, as of June 30, 2015, the Company’s reported stockholders’ equity of \$1,698,000 did not meet the \$2,500,000 minimum required to maintain continued listing as set forth in NASDAQ Rule 5550(b)(1) (the “Rule”), and that as of August 10, 2015, the Company did not meet the alternative requirements of market value of listed securities or net income from continuing operations. In accordance with NASDAQ Rule 5810(c) (2), the Company was given 45 days from the date of the Notice, or until September 25, 2015, to submit to NASDAQ a plan to regain compliance with the continued listing requirements. On September 18, 2015, the Company submitted its plan to regain compliance with the continued listing requirements. By letter dated October 15, 2015, the Company was given until February 8, 2016, to regain compliance with the Rule.

On February 9, 2016, the Company received a Staff Determination Letter (the “Letter”) from NASDAQ notifying it that the Company had not regained compliance with the Rule. The Letter also stated that the Company’s securities would be scheduled for delisting and would be suspended at the opening of business on February 18, 2016 unless the Company requested an appeal of the decision to the Hearings Panel (the “Panel”). The Company requested, and was granted, a hearing before the Panel, which was held on March 31, 2016. This hearing automatically stayed the delisting of the Company’s common stock pending the issuance of a determination by the Panel.

On April 8, 2016, the Company received a determination letter from the Panel notifying the Company that its request for continued listing was granted, subject to two conditions: (1) on or before May 16, 2016, the Company was to provide the Panel with an update on its progress toward compliance, in particular the status of a Form S-1 filing and prospectus for public offering; and (2) on or before August 8, 2016, the Company was to publicly announce and inform the Panel that it has stockholders’ equity above \$2.5 million and provide the Panel with certain updated financial information.

On August 9, 2016, the Company received a determination letter from the Panel notifying the Company that its common stock will be delisted from NASDAQ and that suspension of trading in the shares will be effective at the open of business on August 11, 2016. The determination letter also indicated that NASDAQ would complete the delisting by filing a Form 25 Notification of Delisting with the Securities and Exchange Commission, after applicable appeals periods have lapsed. The delisting becomes effective ten days after the Form 25 is filed.

On August 11, 2016, the Company issued a press release announcing the delisting of the Company’s common stock. Such press release is included as Exhibit 99.1 and is incorporated by reference herein.

### Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Semler Scientific, Inc. Press Release dated August 11, 2016.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEMLER SCIENTIFIC, INC.**

By: /s/ Douglas Murphy-Chutorian  
Name: Douglas Murphy-Chutorian  
Title: Chief Executive Officer

Date: August 11, 2016

---

**Semler Scientific, Inc. To Begin Trading on OTCQB®**

**PORTLAND, Ore.** – August 11, 2016 – Semler Scientific, Inc. (OTCQB: SMLR; “Semler”), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare insurers and physician groups, announced today that its common stock will be delisted from the NASDAQ Capital Market and that suspension of trading in the shares was effective at the open of business on August 11, 2016 for failure to regain compliance with the required \$2,500,000 minimum stockholders’ equity for continued listing within the compliance periods afforded by the NASDAQ’s hearings panel.

Semler expects to begin trading on the OTCQB® on August 11, 2016 under the symbol SMLR. Investors can find current financial disclosure and Real-Time Level 2 quotes for Semler’s stock on [www.otcmarkets.com](http://www.otcmarkets.com).

NASDAQ informed Semler that it would complete the delisting by filing a Form 25 Notification of Delisting with the Securities and Exchange Commission, after applicable appeals periods have lapsed. The delisting becomes effective ten days after the Form 25 is filed.

**About Semler Scientific, Inc.:**

Semler Scientific, Inc., is an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare insurers and physician groups. Our mission is to develop, manufacture and market innovative proprietary products and services that assist our customers in evaluating and treating chronic diseases. Our first patented and U.S. Food and Drug Administration, or FDA, cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. In March 2015 we received FDA 510(k) clearance for the next generation version of this product named QuantaFlo™, which was commercially launched in August 2015. In April 2015, we launched our multi-test service platform, WellChec™, to more comprehensively evaluate our customers’ patients for chronic disease, including heart attacks and strokes. We believe the combination of our proprietary test, QuantaFlo™, and our multi-test service platform, WellChec™, position us to provide valuable information to our insurance company and physician customers, which in turn permit them to better guide patient care. Additional information about Semler can be found at [semlerscientific.com](http://semlerscientific.com).

**CONTACT:**

Susan A. Noonan  
S.A. Noonan Communications  
[susan@sanoonan.com](mailto:susan@sanoonan.com)  
212 966 3650

**SOURCE:** Semler Scientific, Inc.

####

---